在模拟脑脊液浓度曲线的药效学模型中，头孢匹罗对来自脑膜炎患者的耐青霉素肺炎链球菌分离株的杀菌活性。
Killing activity of cefpirome against penicillin-resistant Streptococcus pneumoniae isolates from patients with meningitis in a pharmacodynamic model simulating the cerebrospinal fluid concentration profile.
作者信息
Fitoussi F, Doit C, Sandin A, Pechinot A, Kazmierczack A, Geslin P, Bingen E
机构信息
Service de Microbiologie, Hôpital Robert Debré, Paris, France.
出版信息
Antimicrob Agents Chemother. 1995 Nov;39(11):2560-3. doi: 10.1128/AAC.39.11.2560.
Abstract
An in vitro pharmacodynamic model was used to determine the killing kinetics of cefpirome against 20 Streptococcus pneumoniae strains (penicillin G MICs, > 0.125 to 2 micrograms/ml) isolated from patients with meningitis. The concentration of cefpirome was adjusted dynamically to simulate the median concentration profile obtained in the cerebrospinal fluid of adults after the infusion of a single dose of 2 g. The cefpirome MIC at which 90% of isolates are inhibited was 0.5 microgram/ml. Bactericidal activity was observed at 6 h, with mean killing of 3.51 +/- 0.34 log10 CFU/ml for all strains for which the cefpirome MIC was < 0.5 microgram/ml. In contrast, for strains for which the cefpirome MIC was > or = 0.5 microgram/ml, killing was significantly less (P < 0.05), with a mean reduction of only 2.86 +/- 0.57 log10 CFU/ml.
摘要
采用体外药效学模型来确定头孢匹罗对从脑膜炎患者分离出的20株肺炎链球菌（青霉素G的最低抑菌浓度，>0.125至2微克/毫升）的杀菌动力学。动态调整头孢匹罗的浓度，以模拟单剂量输注2克后在成人脑脊液中获得的中位浓度曲线。90%分离株被抑制时的头孢匹罗最低抑菌浓度为0.5微克/毫升。在6小时时观察到杀菌活性，对于头孢匹罗最低抑菌浓度<0.5微克/毫升的所有菌株，平均杀菌量为3.51±0.34 log10 CFU/毫升。相比之下，对于头孢匹罗最低抑菌浓度≥0.5微克/毫升的菌株，杀菌量明显较少（P<0.05），平均仅减少2.86±0.57 log10 CFU/毫升。
相似文献
1
Killing activity of cefpirome against penicillin-resistant Streptococcus pneumoniae isolates from patients with meningitis in a pharmacodynamic model simulating the cerebrospinal fluid concentration profile.
Antimicrob Agents Chemother. 1995 Nov;39(11):2560-3. doi: 10.1128/AAC.39.11.2560.
2
Comparative in vitro killing activities of meropenem, imipenem, ceftriaxone, and ceftriaxone plus vancomycin at clinically achievable cerebrospinal fluid concentrations against penicillin-resistant Streptococcus pneumoniae isolates from children with meningitis.
Antimicrob Agents Chemother. 1998 Apr;42(4):942-4. doi: 10.1128/AAC.42.4.942.
3
Assessment of the activity of ceftaroline against clinical isolates of penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic model.
J Antimicrob Chemother. 2012 Jul;67(7):1706-11. doi: 10.1093/jac/dks113. Epub 2012 Mar 30.
4
Ceftriaxone acts synergistically with levofloxacin in experimental meningitis and reduces levofloxacin-induced resistance in penicillin-resistant pneumococci.
J Antimicrob Chemother. 2004 Feb;53(2):305-10. doi: 10.1093/jac/dkh082. Epub 2004 Jan 16.
5
Cefepime is efficacious against penicillin- and quinolone-resistant pneumococci in experimental meningitis.
J Antimicrob Chemother. 2002 Feb;49(2):327-30. doi: 10.1093/jac/49.2.327.
6
In vitro killing of penicillin-susceptible, -intermediate, and -resistant strains of Streptococcus pneumoniae by cefotaxime, ceftriaxone, and ceftizoxime: a comparison of bactericidal and inhibitory activity with achievable CSF levels.
Diagn Microbiol Infect Dis. 1995 May-Jun;22(1-2):35-42. doi: 10.1016/0732-8893(95)00094-q.
7
Antimicrobial therapy of experimental meningitis caused by Streptococcus pneumoniae strains with different susceptibilities to penicillin.
Antimicrob Agents Chemother. 1985 Feb;27(2):141-5. doi: 10.1128/AAC.27.2.141.
8
Antibiotic therapy and acute outcome of meningitis due to Streptococcus pneumoniae considered intermediately susceptible to broad-spectrum cephalosporins.
Antimicrob Agents Chemother. 1994 May;38(5):918-23. doi: 10.1128/AAC.38.5.918.
9
In vitro susceptibility of Streptococcus pneumoniae strains to nine beta-lactam antibiotics and the killing kinetics of cephalosporins alone and in combination with vancomycin or gentamicin.
Microb Drug Resist. 1996 Fall;2(3):361-9. doi: 10.1089/mdr.1996.2.361.
10
In vitro activities of cefotaxime, ceftriaxone, ceftazidime, cefpirome, and penicillin against Streptococcus pneumoniae isolates.
Antimicrob Agents Chemother. 1995 Oct;39(10):2193-6. doi: 10.1128/AAC.39.10.2193.
引用本文的文献
1
Pharmacokinetic and pharmacodynamic parameters of antimicrobials: potential for providing dosing regimens that are less vulnerable to resistance.
Clin Pharmacokinet. 2009;48(8):517-28. doi: 10.2165/10895960-000000000-00000.
2
Comparative in vitro killing activities of meropenem, imipenem, ceftriaxone, and ceftriaxone plus vancomycin at clinically achievable cerebrospinal fluid concentrations against penicillin-resistant Streptococcus pneumoniae isolates from children with meningitis.
Antimicrob Agents Chemother. 1998 Apr;42(4):942-4. doi: 10.1128/AAC.42.4.942.
3
Cefpirome. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia.
Drugs. 1997 Jul;54(1):117-40. doi: 10.2165/00003495-199754010-00013.
4
Antipneumococcal activities of cefpirome and cefotaxime, alone and in combination with vancomycin and teicoplanin, determined by checkerboard and time-kill methods.
Antimicrob Agents Chemother. 1996 Sep;40(9):1973-6. doi: 10.1128/AAC.40.9.1973.
本文引用的文献
1
Killing kinetics of cefuroxime against Streptococcus pneumoniae in an in vitro model simulating serum concentration profiles after intramuscular administration.
Eur J Clin Microbiol Infect Dis. 1993 Apr;12(4):297-9. doi: 10.1007/BF01967263.
2
Cefotaxime breakpoint for Streptococcus pneumoniae.
Antimicrob Agents Chemother. 1993 Mar;37(3):616-7. doi: 10.1128/AAC.37.3.616.
3
Dilemmas in diagnosis and management of cephalosporin-resistant Streptococcus pneumoniae meningitis.
Pediatr Infect Dis J. 1993 Mar;12(3):196-200. doi: 10.1097/00006454-199303000-00004.
4
Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis.
Antimicrob Agents Chemother. 1993 Aug;37(8):1630-6. doi: 10.1128/AAC.37.8.1630.
5
Treatment failure with use of a third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and review.
Clin Infect Dis. 1994 Feb;18(2):188-93. doi: 10.1093/clinids/18.2.188.
6
Management of infections caused by antibiotic-resistant Streptococcus pneumoniae.
N Engl J Med. 1994 Aug 11;331(6):377-82. doi: 10.1056/NEJM199408113310607.
7
In vitro killing activities of antibiotics at clinically achievable concentrations in cerebrospinal fluid against penicillin-resistant Streptococcus pneumoniae isolated from children with meningitis.
Antimicrob Agents Chemother. 1994 Nov;38(11):2655-9. doi: 10.1128/AAC.38.11.2655.
8
Experimental pneumococcal meningitis: role of leukocytes in pathogenesis.
Infect Immun. 1983 Jul;41(1):275-9. doi: 10.1128/iai.41.1.275-279.1983.
9
Bactericidal versus bacteriostatic antibiotic therapy of experimental pneumococcal meningitis in rabbits.
J Clin Invest. 1983 Mar;71(3):411-9. doi: 10.1172/jci110785.
10
Relatively penicillin-resistant pneumococcal infections in pediatric patients.
Pediatr Infect Dis. 1984 Mar-Apr;3(2):129-32. doi: 10.1097/00006454-198403000-00010.
Zotero 插件